Anileridine
Synthetic opioid analgesic
Anileridine | |
---|---|
[[File:|frameless|220px|alt=|]] | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Anileridine is a synthetic opioid analgesic that is structurally related to pethidine (meperidine). It was developed in the 1950s by the pharmaceutical company Merck & Co. as a potential alternative to pethidine with a better side effect profile.
Pharmacology
Anileridine works by binding to the opioid receptors in the central nervous system, which leads to the inhibition of pain signals. It is primarily used for the management of moderate to severe pain. The drug has a similar mechanism of action to other opioids, such as morphine and fentanyl, but with some differences in its pharmacokinetic properties.
Medical Uses
Anileridine is indicated for the relief of moderate to severe pain. It is often used in a hospital setting for postoperative pain management and in patients who require continuous pain relief. The drug can be administered orally or via intravenous injection.
Side Effects
Common side effects of anileridine include nausea, vomiting, dizziness, and constipation. Like other opioids, it has the potential for abuse and dependence. Overdose can lead to severe respiratory depression and death.
Legal Status
Anileridine is classified as a controlled substance in many countries due to its potential for abuse and dependence. In the United States, it is listed as a Schedule II controlled substance under the Controlled Substances Act.
History
Anileridine was first synthesized in the 1950s by Merck & Co. It was introduced as a potential alternative to pethidine, with the aim of providing effective pain relief with fewer side effects. However, its use has declined over the years with the development of newer analgesics.
See Also
References
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD